Hypertension and atrial fibrillation. Issue 12 (4th December 2022)

• Record Type: Journal Article
• Authors: Middeldorp, Melissa E.; Ariyaratnam, Jonathan P.; Kamsani, Suraya H.; Albert, Christine M.; Sanders, Prashanthan
• Is Part Of: Journal of hypertension. Volume 40:Issue 12(2022)
• Page Start: 2337
• Page End: 2352
• Publication Date: 2022-12-04
• Subjects: atrial fibrillation -- hypertension -- outcomes -- remodelling; Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/HJH.0000000000003278
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Hypertension is the most prevalent cardiovascular risk factor underlying atrial fibrillation and is present in up to 40% of patients with atrial fibrillation. Furthermore, attributable risk studies have shown that a history of hypertension contributes to up to 24% of incident atrial fibrillation. New data suggest that even early forms of hypertension (prehypertension and aortic stiffness) are associated with an increased risk of atrial fibrillation development. Hypertension and prehypertension are therefore critical mediators for the development of atrial fibrillation. Mechanisms for the association between hypertension and atrial fibrillation include diffuse electro-structural changes to the left atrium, driven by the haemodynamic and neurohormonal influences of hypertension and other, frequently coexisting, cardiovascular risk factors. Management of hypertension in atrial fibrillation should focus not only on blood pressure reduction but also on a comprehensive risk factor modification strategy. Such strategies have been shown to be associated with significant improvements in atrial fibrillation symptom burden as well as improved arrhythmia-free survival and reversal of the progression of atrial fibrillation. These strategies should focus on dietary modifications as well as prescribed exercise programmes involving a multidisciplinary team and patient-centred atrial fibrillation care. Risk factor management, supplemented by antihypertensive medications as needed, provides the optimum strategy for improving outcomes and even reversing the natural progression of atrial fibrillation in patients with hypertension.